Functional Dynamics of Thrombin

凝血酶的功能动力学

基本信息

项目摘要

 DESCRIPTION (provided by applicant): The proposed studies will provide a quantitative and predictive understanding of coagulation protease dynamics in relation to catalytic function and allosteric control. Cascades of serine proteases, the largest of all of the peptidase families, control coagulation. Control of function and regulation of the coagulation and anticoagulation proteases very likely involves dynamic allostery, however, no studies have measured the dynamics of coagulation proteases. Thrombin provides the switch between coagulation and anti-coagulation, and is allosterically regulated by thrombomodulin (TM) binding. In dynamic allostery, the protein exists in an ensemble of states that rapidly interconvert, and sub-populations of states are selected when an allosteric effector binds. NMR dynamics experiments are the only way to observe interconverting sub-states in allosteric proteins. We therefore propose NMR backbone and side chain dynamics experiments combined with enhanced sampling molecular dynamics (aMD) simulations to fully describe dynamic motions in apo-thrombin, PPACK-thrombin, two W215 mutants of thrombin and the thrombin-TM456 complex. The goal of the project is to obtain quantitative dynamic data that will be used to calibrate aMD simulations. Once calibrated, the simulations could predict dynamic allostery in other proteases involved in coagulation that are not amenable to NMR. The three complementary aims of the project are: Aim 1. Determine the dynamic motions in thrombin that are important for catalytic function. Accelerated MD (aMD) simulations and NMR experiments will be performed to probe motions on time scales from ns to ms in the apo, and PPACK-bound forms of human α-thrombin. Our hypothesis is that by comparing results from apo and PPACK-thrombin we will be able to discover those motions which change upon substrate binding, and are therefore likely to be important for catalytic activity. Aim 2. Determine the dynamic motions in thrombin that are important for allosteric control. Extended aMD simulations will help interpret the experimental results and conversely the NMR results will provide quantitative information about rates of correlated backbone motions with which to validate the simulations. Two W215 mutant forms of thrombin and also the thrombin-TM456 complex will be studied. Our published 10 ns aMD simulations on thrombin-TM456 show that TM causes the disparate motions in thrombin to coalesce into correlated motions. Our hypothesis is that differences in dynamics between different allosteric forms of thrombin will reveal the mechanism of dynamic allostery in thrombin and other serine proteases. Aim 3. Develop side chain dynamics experiments to probe the dynamic allostery between effector-binding sites and the active site of thrombin. The side chain dynamics results will be iteratively interpreted in light of extended aMD simulations. Hypothesis: That side chain dynamics, which have been shown to play a critical role in conformational entropy, also play a critical role in thrombin allostery.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ELIZABETH A. KOMIVES其他文献

ELIZABETH A. KOMIVES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ELIZABETH A. KOMIVES', 18)}}的其他基金

The landscape of NFκB transcription dynamics
NFκB 转录动力学景观
  • 批准号:
    10444634
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
The landscape of NFκB transcription dynamics
NFκB 转录动力学景观
  • 批准号:
    10686820
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
Administrative Supplement for Flow Quench Instrument
流动淬火仪行政补充
  • 批准号:
    10799448
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
Molecular Biophysics Training Grant at UC San Diego
加州大学圣地亚哥分校分子生物物理学培训补助金
  • 批准号:
    10418781
  • 财政年份:
    2021
  • 资助金额:
    $ 36.37万
  • 项目类别:
Molecular Biophysics Training Grant at UC San Diego
加州大学圣地亚哥分校分子生物物理学培训补助金
  • 批准号:
    10269570
  • 财政年份:
    2021
  • 资助金额:
    $ 36.37万
  • 项目类别:
Molecular Biophysics Training Grant at UC San Diego
加州大学圣地亚哥分校分子生物物理学培训补助金
  • 批准号:
    10615137
  • 财政年份:
    2021
  • 资助金额:
    $ 36.37万
  • 项目类别:
Synapt G2-S System with HXMS Automation
具有 HXMS 自动化功能的 Synapt G2-S 系统
  • 批准号:
    8447332
  • 财政年份:
    2013
  • 资助金额:
    $ 36.37万
  • 项目类别:
BACKBONE DYNAMICS OF THROMBIN AND THROMBIN-THROMBOMODULIN COMPLEXES
凝血酶和凝血酶-血栓调节蛋白复合物的骨架动力学
  • 批准号:
    8361179
  • 财政年份:
    2011
  • 资助金额:
    $ 36.37万
  • 项目类别:
BACKBONE DYNAMICS OF THROMBIN AND THROMBIN-THROMBOMODULIN COMPLEXES
凝血酶和凝血酶-血栓调节蛋白复合物的骨架动力学
  • 批准号:
    8168987
  • 财政年份:
    2010
  • 资助金额:
    $ 36.37万
  • 项目类别:
IkB/NF-kB Recognition In Silico, In Vitro and In Vivo
IkB/NF-kB 计算机、体外和体内识别
  • 批准号:
    7924964
  • 财政年份:
    2009
  • 资助金额:
    $ 36.37万
  • 项目类别:

相似海外基金

An Anticoagulation-Free Artificial Placenta Device
一种免抗凝人工胎盘装置
  • 批准号:
    10741704
  • 财政年份:
    2023
  • 资助金额:
    $ 36.37万
  • 项目类别:
Research Supplement to Promote Diversity Supplement for the ECMO without Anticoagulation
研究补充促进无抗凝 ECMO 的多样性补充
  • 批准号:
    10712181
  • 财政年份:
    2023
  • 资助金额:
    $ 36.37万
  • 项目类别:
心原性ショックに対するTheragnostic Anticoagulationに向けた生体応答ダイナミクス
治疗诊断抗凝治疗心源性休克的生物反应动力学
  • 批准号:
    23K19561
  • 财政年份:
    2023
  • 资助金额:
    $ 36.37万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Net Clinical Benefit and Cost-Effectiveness of Indefinite Anticoagulation Among Clinically Relevant Subgroups of Patients with First Unprovoked Venous Thromboembolism
首次无端静脉血栓栓塞临床相关亚组患者无限期抗凝的净临床效益和成本效益
  • 批准号:
    493128
  • 财政年份:
    2023
  • 资助金额:
    $ 36.37万
  • 项目类别:
Combined Use of Polycarboxybetaine Coatings with a Selective FXIIa Inhibitor to Create Potent Biomaterial Anticoagulation Without Bleeding During Extracorporeal Life Support
聚羧基甜菜碱涂层与选择性 FXIIa 抑制剂的组合使用可在体外生命支持期间产生有效的生物材料抗凝作用而不会出血
  • 批准号:
    10444025
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
2/2 REACT-AF: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation
2/2 REACT-AF:通过连续监测心房颤动进行抗凝心律评估
  • 批准号:
    10509053
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
Effectiveness and Safety of Transcatheter Left Atrial Appendage Occlusion vs. Anticoagulation in Older Adults with Atrial Fibrillation and Alzheimer's Disease and Related dementias
经导管左心耳封堵术与抗凝治疗对患有心房颤动、阿尔茨海默病及相关痴呆症的老年人的有效性和安全性
  • 批准号:
    10672458
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial (REACT-AF)
心房颤动连续监测试验的抗凝节律评估 (REACT-AF)
  • 批准号:
    10509310
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children
危重儿童连续肾脏替代治疗期间反复抗凝和肾脏监测的低血容量平台
  • 批准号:
    10383224
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children
危重儿童连续肾脏替代治疗期间反复抗凝和肾脏监测的低血容量平台
  • 批准号:
    10820748
  • 财政年份:
    2022
  • 资助金额:
    $ 36.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了